# Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

> **NCT05970679** · PHASE3 · COMPLETED · sponsor: **Daewon Pharmaceutical Co., Ltd.** · enrollment: 252 (actual)

## Conditions studied

- Hypercholesterolemia, Dyslipidemia

## Interventions

- **DRUG:** Ezetimibe/Atorvastatin 10/5 mg
- **DRUG:** Atorvastatin 5mg
- **DRUG:** Ezetimibe 10mg
- **DRUG:** Atorvastatin 10mg
- **DRUG:** DW1125 placebo
- **DRUG:** DW1125A placebo
- **DRUG:** DW1125E placebo
- **DRUG:** DW1125A-1 placebo

## Key facts

- **NCT ID:** NCT05970679
- **Lead sponsor:** Daewon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-17
- **Primary completion:** 2023-04-13
- **Final completion:** 2023-04-13
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05970679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05970679, "Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05970679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*